Expression of octamer-4 in serous and mucinous ovarian carcinoma

Journal of Clinical Pathology

Volumn 63, Issue 10, 2010, Pages 879-883

  Zhang, Jing ^a   Li, Yan Li ^a   Zhou, Cai Yun ^a   Hu, Yu Ting ^a   Chen, Huai Zeng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYSTADENOMA; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE TUBE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; CYSTADENOMA; DISEASE PROGRESSION; EPITHELIUM; FALLOPIAN TUBES; FEMALE; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; OCTAMER TRANSCRIPTION FACTOR-3; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL;

EID: 77957835482     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.073593     Document Type: Article

References (26)

1. Bengtsson S, Krogh M, Szigyarto CA, et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res 2007;6:1440-50. (Pubitemid 46724042)
2. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88. (Pubitemid 32458162)
3. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-18.
4. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004;191:718-32. (Pubitemid 39298100)
5. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
6. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-7.
7. Pesce M, Gross MK, Schöler HR. In line with our ancestors: Oct-4 and the mammalian germ. Bioessays 1998;20:722-32.
8. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24:372-6. (Pubitemid 30187435)
9. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
10. Sung MT, Jones TD, Beck SD, et al. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol 2006;37:662-7.
11. Chen Z, Xu WR, Qian H, et al. Oct4, a novel marker for human gastric cancer. J Surg Oncol 2009;99:414-19.
12. Du Z, Jia D, Liu S, et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 2009;57:724-33.
13. Ezeh UI, Turek PJ, Reijo RA, et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-65.
14. Karoubi G, Gugger M, Schmid R, et al. OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 2009;8:393-7.
15. Hochedlinger K, Yamada Y, Beard C, et al. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005;121:465-77. (Pubitemid 40692305)
16. Gidekel S, Pizov G, Bergman Y, et al. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-70. (Pubitemid 37491097)
17. Chen H, Chen X, Ye F, et al. Symmetric division and expression of its regulatory gene Numb in human cervical squamous carcinoma cells. Pathobiology 2009;76:149-54.
18. Maulbecker CC, Gruss P. The oncogenic potential of deregulated homeobox genes. Cell Growth Differ 1993;4:431-41.
19. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1-7.
20. Serov SF, Scully RE, Sobin LH. International histological classification and staging of tumours. No 9. Histologic typing of ovarian tumours. Geneva: World Health Organisation, 1973.
21. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004;28:1341-6. (Pubitemid 39336373)
22. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4. (Pubitemid 38018236)
23. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010:932371.
24. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60.
25. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
26. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-18.